Immix Biopharma (IMMX) said Tuesday six patients dosed in a phase 1b safety run-in segment of a trial of its experimental NXC-201 treatment of relapsed or refractory AL Amyloidosis successfully completed the trial's safety evaluation.
The safety run-in segment dosed three patients at 150 million CAR-T cells and three patients at 450 million CAR-T cells.
Immix said enrollment can now advance across US study sites at a dose of 450 million CAR-T cells.
AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow.
Price: 2.29, Change: -0.01, Percent Change: -0.43
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。